Clinical trial · Interventional
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort
NCT02228473CI-TRIAL-00015916unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of catheter-related bladder discomfort.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anesthesia | — | UNRESOLVED | — |
| Catheter Site Discomfort | — | UNRESOLVED | — |
| Complications | — | UNRESOLVED | — |
| Urinary Bladder Neoplasms | Bladder Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atropine | Drug | — | UNRESOLVED |
| Glycopyrrolate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Glycopyrrolate
- description
- Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
- interventionNames
- Drug: Glycopyrrolate
- type
- ACTIVE_COMPARATOR
- label
- Atropine
- description
- Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
- interventionNames
- Drug: Atropine
Primary outcomes (1)
- measure
- Catheter-related bladder discomfort
- timeFrame
- 1 hour postoperatively
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients scheduled for transurethral bladder excision under general anesthesia * ASA I-III Exclusion Criteria: * Foley catheter less than 18 Fr. * Patients with obstruction of urinary tract * Patients with neurogenic bladder * Patients with severe obesity * Patients with neurologic disorder * Patients with chronic pain * Patients with allergic history to atropine or glycopyrrolate
References
Publications (1)
- DERIVEDKim HC, Lim SM, Seo H, Park HP. Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study. J Anesth. 2015 Dec;29(6):831-5. doi: 10.1007/s00540-015-2064-2. Epub 2015 Aug 9. PMID 26254585